Artiva Biotherapeutics, Inc. (ARTV) is a Healthcare stock trading at $10.93 (as of 2026-08-21), with a market capitalization of $543.66M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company developing off-the-shelf natural killer (NK) cell therapies and allogeneic CAR-NK product candidates. Its programs include AB-101 for autoimmune diseases and cancers and additional candidates including AB-201 and AB-205, targeting conditions such as lupus nephritis, rheumatoid arthritis, and certain lymphomas.
Understand Artiva Biotherapeutics, Inc.: how it makes money
Artiva Biotherapeutics develops off-the-shelf NK cell therapies, led by AB-101, for patients with autoimmune diseases and cancers, currently focused on clinical development rather than described product sales.
The profit model largely depends on translating AB-101 clinical progress into broader real-world adoption, measured by how many patients are treated and how many active clinical sites are using AlloNK (including combination settings).
Business quality (Weak): Data is limited to a single quarter and provides no reportable revenue segments, but it does include multiple clinical operating metrics for AlloNK and AB-101.
Bull case
Clear clinical focus on AB-101 off-the-shelf NK cell therapy across autoimmune diseases and cancers: The lead product candidate is AB-101 (off-the-shelf NK cell therapy) and the provided operating metrics track AlloNK use in autoimmune patients.
Early adoption signals in clinical activity metrics: The latest provided clinical metrics include 70.0 Autoimmune Patients Treated With AlloNK and 40.0 Active Clinical Sites Treating AlloNK.
Reported response rate in an autoimmune efficacy measure: The American College of Rheumatology Fifty Response Rate is 71.0 percent (provided operating metric).
Bear case
Loss-making profile in the latest quarter: For the period ended 2024-09-30, operating_margin_pct is -7304.8 and revenue_b is 0.0.
Outcome and durability risk implied by the need for follow-up-based metrics: Several provided metrics are based on patients with at least six months or at least twelve weeks of follow-up, suggesting results need time to validate durability.
Dependency on continued clinical site activity and treatment expansion: The operating metrics emphasize Active Clinical Sites Treating AlloNK and patient treatment counts, which can change if enrollment, trial conduct, or partner decisions shift.